- Strong underlying H1 performance: Revenue +7.4%, Core Earnings +12.7% and Core EPS +49.3%-
- Strong first half results led by Growth Drivers
Takeda's Growth Drivers delivered 15.3% Revenue growth
Underlying Revenue growth across all regions, led by continued double-digit performance in the US
"Today we reported strong first half results in a year of significant transformation. This strong momentum allows us to increase our full year profit guidance.
The recent positive CHMP opinion for the conditional approval of NINLARO® in the EU was an important step to bring this new treatment option to patients worldwide. I am confident that our Growth Drivers will continue to fuel our momentum well into the future."
Reported Results for H1 (April – September) of FY2016
|EPS||69 yen||159 yen||+129.4%||N/A|
|Core EPS||138 yen||139 yen||+1.2%||+49.3%|
1 Core Earnings is calculated by taking reported gross profit and deducting SG&A expenses and R&D expenses.
In addition, certain other items that are non-core in nature and significant in value may also be adjusted.
2 Underlying growth compares two periods of financial results under a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures.
3 Attributable to the owners of the company.
Takeda increases management guidance for Underlying Core Earnings to "mid- to high-teen growth" and Underlying Core EPS is trending to the high end of the "low- to mid-teen growth" range
(May 10, 2016)
(Oct 28, 2016)
|Underlying Revenue||Mid single digit growth (%)||Mid single digit growth (%)|
|Underlying Core Earnings||Low- to mid-teen growth (%)||Mid- to high-teen growth (%)|
|Underlying Core EPS||Low- to mid-teen growth (%)||Low- to mid-teen growth (%)|
|Annual Dividend per Share||180 yen||180 yen|
Reported Net Profit/EPS forecast increased despite accelerated R&D transformation costs and unfavorable currency impact
Total estimated costs related to the R&D transformation program are unchanged at 75 billion yen; with 40 billion yen estimated in FY2016 (previous forecast was 25 billion yen) and 35 billion yen in FY2017.
|(billion yen)||Previous Forecast
(May 10, 2016)
(Oct 28, 2016)
|Net Profit 3||88.0||91.0|
|EPS||112 yen||116 yen|
|Exchange Rate (annual average)||1 US$=110 yen, 1 euro=125 yen||1 US$=104 yen, 1 euro=117 yen|
1 Includes unfavorable currency impact of approximately 68 billion yen
2 Includes favorable currency impact of approximately 14 billion yen
3 Attributable to the owners of the company
For more details on Takeda’s FY2016 H1 results and other financial information please visit http://www.takeda.com/investor-information/results/
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.
Noriko Higuchi, +81-(0)3-3278-2306
Tsuyoshi Tada, +81 (0)3-3278-2417,